Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th
Nutriband Inc. (Nasdaq: NTRB) has announced its participation in the Noble Conference at Florida Atlantic University in Boca Raton on December 3rd-4th, 2024. Company President and Chairman Serguei Melnik will present on December 4th at 1:30 PM in Conference Room 3, focusing on the company's AVERSA technology.
The company specializes in developing transdermal pharmaceutical products, with their flagship product being an abuse-deterrent fentanyl patch incorporating AVERSA™ technology. This innovative technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Presentation details and replay will be available on Channelchek and Youtube after the conference.
Nutriband Inc. (Nasdaq: NTRB) ha annunciato la sua partecipazione alla Noble Conference presso la Florida Atlantic University a Boca Raton il 3-4 dicembre 2024. Il Presidente e Chairman dell'azienda, Serguei Melnik, presenterà il 4 dicembre alle 13:30 nella Sala Conferenze 3, focalizzandosi sulla tecnologia AVERSA dell'azienda.
L'azienda è specializzata nello sviluppo di prodotti farmaceutici transdermici, con il loro prodotto di punta rappresentato da un cerotto per il fentanyl deterrente all'uso improprio che incorpora la tecnologia AVERSA™. Questa tecnologia innovativa può essere integrata in qualsiasi cerotto transdermico per prevenire abusi, utilizzi impropri, deviazioni e esposizioni accidentali a farmaci con potenziale d'abuso.
I dettagli della presentazione e la registrazione saranno disponibili su Channelchek e Youtube dopo la conferenza.
Nutriband Inc. (Nasdaq: NTRB) ha anunciado su participación en la Noble Conference en la Universidad Atlantic de Florida en Boca Ratón del 3 al 4 de diciembre de 2024. El Presidente y Presidente de la empresa, Serguei Melnik, presentará el 4 de diciembre a la 1:30 PM en la Sala de Conferencias 3, centrándose en la tecnología AVERSA de la empresa.
La empresa se especializa en el desarrollo de productos farmacéuticos transdérmicos, siendo su producto insignia un parche de fentanilo disuasorio de abuso que incorpora la tecnología AVERSA™. Esta tecnología innovadora puede integrarse en cualquier parche transdérmico para prevenir el abuso, el uso indebido, la desviación y la exposición accidental a medicamentos con potencial de abuso.
Los detalles de la presentación y la repetición estarán disponibles en Channelchek y Youtube después de la conferencia.
뉴트리밴드 주식회사 (Nasdaq: NTRB)는 2024년 12월 3일부터 4일까지 보카 레이톤에 위치한 플로리다 애틀랜틱 대학교에서 열리는 노블 컨퍼런스에 참여한다고 발표했습니다. 회사의 사장 겸 회장인 세르게이 멜니크가 12월 4일 오후 1시 30분에 회의실 3에서 AVERSA 기술에 대해 발표할 예정입니다.
이 회사는 경피 약리 제품 개발을 전문으로 하며, 자사의 주력 제품은 AVERSA™ 기술을 통합한 남용 저항성 펜타닐 패치입니다. 이 혁신적인 기술은 모든 경피 패치에 통합되어 남용, 오용, 전이 및 남용 잠재력이 있는 약물의 우발적인 노출을 예방할 수 있습니다.
발표 세부 사항 및 재생은 회의 후 Channelchek 및 Youtube에서 확인할 수 있습니다.
Nutriband Inc. (Nasdaq: NTRB) a annoncé sa participation à la Noble Conference à l'Université Atlantic de Floride à Boca Raton, les 3 et 4 décembre 2024. Le Président et Président de l'entreprise, Serguei Melnik, présentera le 4 décembre à 13h30 dans la Salle de Conférence 3, en se concentrant sur la technologie AVERSA de l'entreprise.
L'entreprise est spécialisée dans le développement de produits pharmaceutiques transdermiques, son produit phare étant un patch de fentanyl résistant à l'abus intégrant la technologie AVERSA™. Cette technologie innovante peut être intégrée dans n'importe quel patch transdermique pour prévenir l'abus, le mauvais usage, la déviation et l'exposition accidentelle à des médicaments ayant un potentiel d'abus.
Les détails de la présentation et la rediffusion seront disponibles sur Channelchek et Youtube après la conférence.
Nutriband Inc. (Nasdaq: NTRB) hat seine Teilnahme an der Noble Conference an der Florida Atlantic University in Boca Raton für den 3.-4. Dezember 2024 angekündigt. Der Präsident und Vorsitzende des Unternehmens, Serguei Melnik, wird am 4. Dezember um 13:30 Uhr im Konferenzraum 3 präsentieren und sich dabei auf die AVERSA-Technologie des Unternehmens konzentrieren.
Das Unternehmen ist auf die Entwicklung von transdermalen pharmazeutischen Produkten spezialisiert, wobei das Flaggschiffprodukt ein missbrauchsverhinderndes Fentanyl-Patch ist, das die AVERSA™-Technologie integriert. Diese innovative Technologie kann in jedes transdermale Pflaster integriert werden, um Missbrauch, Fehlgebrauch, Umleitung und unbeabsichtigte Exposition gegenüber Arzneimitteln mit Missbrauchspotenzial zu verhindern.
Die Details zur Präsentation und die Aufzeichnung werden nach der Konferenz auf Channelchek und Youtube verfügbar sein.
- None.
- None.
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4th to primarily discuss the company’s AVERSA technology.
Information about the Conference can be found here – https://nobleconference.com
Details of Mr. Melniks presentation and live replay will be available on Channelchek and Youtube after the conference.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q’s filed subsequent to the Form 10-K in 2024, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
FAQ
When is Nutriband (NTRB) presenting at the 2024 Noble Conference?
What is Nutriband's (NTRB) AVERSA technology used for?
What is Nutriband's (NTRB) main product under development?
Where can investors watch Nutriband's (NTRB) Noble Conference presentation?
